Premium
Effects of anandamide and other CB1 ligands on cognitive function
Author(s) -
Kangas Brian D.,
Bergman Jack
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1097.10
Subject(s) - anandamide , cannabinoid , pharmacology , cannabinoid receptor , endocannabinoid system , cognition , potency , drug , cannabis , psychology , chemistry , medicine , neuroscience , antagonist , receptor , in vitro , psychiatry , biochemistry
The primary psychoactive ingredient of marijuana, Δ 9 ‐ tetrahydrocannabinol (THC), has medicinal effects that promote continued development of CB 1 agonists as therapeutics but also produces well‐documented deleterious effects on cognitive endpoints. In the present study, CB 1 agonists—THC (0.03–1.8 mg/kg), WIN 55,212 (0.3–1.8 mg/kg), AM4054 (0.003–0.1 mg/kg), anandamide (3.0–32 mg/kg alone and after the FAAH inhibitor URB 597)—were further evaluated by comparing their effects on cognition in nonhuman primates. Drugs were studied using touchscreen procedures to assay learning (repeated acquisition, reversal), motivation (progressive ratio), and, with novel methodology, attention (titrating vigilance). THC, WIN, and AM4054 produced dose‐related impairment of each type of complex behavior. However, drug potency varied across tasks, i.e., particular cognitive endpoints appeared more vulnerable to drug action (e.g., learning